Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699773 | 0.90 | SCD5 (0.42) | RBP4SCD5CNR1 | |
| SCHEMBL3688369 | 0.85 | SCD5 (0.42) | RBP4SCD5CNR1 | |
| SCHEMBL3692456 | 0.83 | SCD5 (0.54) | RBP4SCD5CNR1 | |
| SCHEMBL3689990 | 0.82 | KDM5A (0.45) | RBP4SCD5CNR1 | |
| SCHEMBL3689646 | 0.81 | SCD5 (0.46) | RBP4SCD5CNR1 | |
| SCHEMBL3686632 | 0.81 | SCD5 (0.49) | RBP4SCD5CNR1 | |
| SCHEMBL3648184 | 0.81 | SCD5 (0.42) | RBP4SCD5CNR1 | |
| SCHEMBL3695977 | 0.80 | SCD5 (0.44) | RBP4SCD5CNR1 | |
| SCHEMBL3688733 | 0.80 | SCD5 (0.47) | RBP4SCD5CNR1 | |
| SCHEMBL3694207 | 0.80 | SCD5 (0.44) | RBP4SCD5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | RBP4 1868/4885SCD5 2314/4885CNR1 524/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | RBP4 1868/4885SCD5 2314/4885CNR1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.